{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.ibrexafungerp","code":"thing-q27273787","url":"https://ver.cy/models/thing/q27273787/","name":"ibrexafungerp","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Ibrexafungerp is a semisynthetic triterpenoid antifungal derived from enfumafungin that inhibits fungal β-(1,3)-D-glucan synthase, disrupting synthesis of a major fungal cell-wall component.","purpose":"Enable an AI agent to recognize ibrexafungerp, assess the identity and fitness of its material forms, and connect antifungal evidence to justified handling and use decisions.","scope":{"in":["Molecular identity, stereochemistry, synonyms, and verified chemical identifiers","Distinction between ibrexafungerp active moiety, citrate salt, and formulated material","Batch composition, purity, impurities, physical state, and stability","Glucan-synthase inhibition and organism-specific antifungal evidence","Substance-level exposure, hazard, and regulatory relationships"],"out":["BREXAFEMME tablet formulation, packaging, and commercial inventory","Patient diagnosis, prescribing, and individualized treatment selection","Candida organism taxonomy and candidiasis disease models","Manufacturing plant operations and complete synthesis procedures","Clinical-trial operations and full study datasets"],"boundaries":[]},"distinguishingFeatures":["Require agreement with a stereochemically specified molecular reference; a name or molecular formula alone cannot establish identity.","Distinguish the active moiety from its 1:1 citrate form before comparing mass or composition. The product label explicitly distinguishes these quantities. [DailyMed, section 11](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c33be3a1-c4fd-512c-e053-2995a90a63eb)","Classify its antifungal action through glucan-synthase inhibition and its triterpenoid structure, rather than treating all antifungals as interchangeable. [DailyMed, section 12.4](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c33be3a1-c4fd-512c-e053-2995a90a63eb)","Treat a tablet containing ibrexafungerp as a related product, not as a pure specimen of the registered substance."],"structure":{"bundles":[{"id":"molecular-identity-and-form","name":"Molecular identity and form","description":"Establish what counts as ibrexafungerp and how a specimen relates to its active moiety.","layers":[{"id":"structure-and-identifiers","name":"Structure and identifiers","description":"Anchor the registry name to a verified stereochemical reference.","findings":[{"id":"identity-requires-structure-agreement","name":"Identity requires structure agreement","description":"Record identifier provenance and require structure agreement before merging chemical records.","questions":[{"text":"Which authoritative structure specifies ibrexafungerp connectivity and stereochemistry?","id":"identity-requires-structure-agreement-q01","kind":"definition"},{"text":"Which CAS, PubChem, and other identifiers have been verified against that structure rather than copied from a name match?","id":"identity-requires-structure-agreement-q02","kind":"provenance"}]}]},{"id":"salt-and-active-moiety","name":"Salt and active moiety","description":"Preserve the distinction between the registered chemical identity and the form present in material.","findings":[{"id":"quantity-needs-a-form-basis","name":"Quantity needs a form basis","description":"Every content or molecular-mass value must identify whether it refers to ibrexafungerp, its citrate, or a hydrated or solvated specimen.","questions":[{"text":"Does the specimen contain unsalted ibrexafungerp or a characterized salt, and what establishes counterion stoichiometry?","id":"quantity-needs-a-form-basis-q01","kind":"boundary"},{"text":"What conversion and water or solvent corrections justify expressing its mass as ibrexafungerp equivalents?","id":"quantity-needs-a-form-basis-q02","kind":"measurement"}]}]}]},{"id":"material-quality-and-condition","name":"Material quality and condition","description":"Assess whether an ibrexafungerp specimen is characterized and suitable for its intended role.","layers":[{"id":"assay-and-contaminants","name":"Assay and contaminants","description":"Connect batch identity and content to analytical evidence.","findings":[{"id":"release-requires-batch-evidence","name":"Release requires batch evidence","description":"Record assay, related substances, residual solvents, and relevant contamination checks against the applicable specification.","questions":[{"text":"Which methods distinguish ibrexafungerp from stereoisomeric impurities and degradation products in this batch?","id":"release-requires-batch-evidence-q01","kind":"measurement"},{"text":"What certificate, underlying results, and intended-use specification support accepting or quarantining this material?","id":"release-requires-batch-evidence-q02","kind":"action"}]}]},{"id":"physical-properties-and-stability","name":"Physical properties and stability","description":"Attach physical measurements and storage evidence to the characterized form.","findings":[{"id":"properties-depend-on-specimen-and-conditions","name":"Properties depend on specimen and conditions","description":"Record solubility, thermal behavior, and stability with methods and conditions; distinguish melting from decomposition.","questions":[{"text":"What solubility and thermal-transition measurements exist for this ibrexafungerp form, at which pH, temperature, and pressure?","id":"properties-depend-on-specimen-and-conditions-q01","kind":"measurement"},{"text":"Which stability data support its container, light and humidity controls, storage interval, and retest date?","id":"properties-depend-on-specimen-and-conditions-q02","kind":"action"}]}]}]},{"id":"antifungal-action-and-susceptibility","name":"Antifungal action and susceptibility","description":"Connect ibrexafungerp target activity to evidence about particular fungi.","layers":[{"id":"target-and-effect","name":"Target and effect","description":"Separate molecular target engagement from organism-level response.","findings":[{"id":"mechanism-needs-matched-evidence","name":"Mechanism needs matched evidence","description":"Maintain separate evidence for enzyme inhibition, cell-wall effects, growth inhibition, and killing.","questions":[{"text":"Which experiments establish ibrexafungerp target activity, and which directly measure fungal killing?","id":"mechanism-needs-matched-evidence-q01","kind":"provenance"},{"text":"Under which concentrations and exposure durations was each effect observed?","id":"mechanism-needs-matched-evidence-q02","kind":"measurement"}]}]},{"id":"isolate-response-and-resistance","name":"Isolate response and resistance","description":"Represent susceptibility and resistance at the resolution supported by testing.","findings":[{"id":"susceptibility-is-contextual","name":"Susceptibility is contextual","description":"Store species, isolate, assay conditions, and interpretation authority separately from an activity result.","questions":[{"text":"Which method and pH produced the ibrexafungerp MIC, and is an applicable interpretive breakpoint established?","id":"susceptibility-is-contextual-q01","kind":"measurement"},{"text":"What phenotypic or genetic evidence supports resistance or cross-resistance for this isolate?","id":"susceptibility-is-contextual-q02","kind":"provenance"},{"text":"Does the evidence support only laboratory activity or a clinical claim for the infection concerned?","id":"susceptibility-is-contextual-q03","kind":"boundary"}]}]}]},{"id":"exposure-and-biological-safety","name":"Exposure and biological safety","description":"Represent exposure-dependent effects and the boundaries needed when passing evidence to clinical or laboratory agents.","layers":[{"id":"disposition-and-interactions","name":"Disposition and interactions","description":"Connect exposure observations to formulation, regimen, population, and interacting agents.","findings":[{"id":"interaction-evidence-needs-context","name":"Interaction evidence needs context","description":"CYP3A interactions affect ibrexafungerp exposure; preserve the source and clinical context of each interaction claim. [DailyMed, section 7](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c33be3a1-c4fd-512c-e053-2995a90a63eb)","questions":[{"text":"Which formulation, population, food conditions, and regimen generated each exposure estimate?","id":"interaction-evidence-needs-context-q01","kind":"measurement"},{"text":"Which interaction results were measured in humans, and which remain laboratory predictions?","id":"interaction-evidence-needs-context-q02","kind":"provenance"}]}]},{"id":"clinical-and-occupational-hazards","name":"Clinical and occupational hazards","description":"Keep therapeutic safety evidence distinct from handling classifications for bulk material.","findings":[{"id":"hazard-context-must-remain-explicit","name":"Hazard context must remain explicit","description":"The referenced product label contraindicates pregnancy because of embryo-fetal risk; this does not establish a bulk-material GHS classification. [DailyMed, boxed warning](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c33be3a1-c4fd-512c-e053-2995a90a63eb)","questions":[{"text":"Which toxicology findings apply to ibrexafungerp itself, and what species, route, duration, and exposure support them?","id":"hazard-context-must-remain-explicit-q01","kind":"provenance"},{"text":"Which supplier safety data sheet and occupational assessment govern handling this form and quantity?","id":"hazard-context-must-remain-explicit-q02","kind":"action"}]}]}]},{"id":"product-links-and-use-authority","name":"Product links and use authority","description":"Connect the substance to products and permitted uses without collapsing their identities.","layers":[{"id":"ingredient-to-product","name":"Ingredient to product","description":"Represent ibrexafungerp as an ingredient of separately identified pharmaceutical products.","findings":[{"id":"product-properties-do-not-define-the-substance","name":"Product properties do not define the substance","description":"Link formulation, route, strength, and label records without assigning tablet characteristics to all ibrexafungerp material.","questions":[{"text":"Which product record identifies the ibrexafungerp form and the basis of its stated strength?","id":"product-properties-do-not-define-the-substance-q01","kind":"boundary"},{"text":"Which evidence links this API batch to a particular product batch or research preparation?","id":"product-properties-do-not-define-the-substance-q02","kind":"provenance"}]}]},{"id":"dated-authority-and-restrictions","name":"Dated authority and restrictions","description":"Qualify use claims and restrictions by authority, jurisdiction, and applicability.","findings":[{"id":"use-status-requires-current-evidence","name":"Use status requires current evidence","description":"Record approval, investigational status, supply status, and lot restrictions separately, with dated supporting records.","questions":[{"text":"Which authority and dated record support the proposed product use in the relevant jurisdiction?","id":"use-status-requires-current-evidence-q01","kind":"provenance"},{"text":"Do any current restrictions apply to this supplier, material batch, or linked product lot?","id":"use-status-requires-current-evidence-q02","kind":"action"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-kinds","name":"Kinds and varieties","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these kinds and varieties hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-kinds-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-standards-and-regulation","name":"Standards and regulation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these standards and regulation hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-standards-and-regulation-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of ibrexafungerp this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Explain ibrexafungerp as a triterpenoid antifungal, citing official labelling for its approved uses.","Report warnings, including pregnancy-related warnings, from the label."],"mustNot":["Recommend, dose or adjust ibrexafungerp for a specific person.","Advise use during pregnancy against the label warnings.","Present it as effective for infections outside its approved uses without evidence.","Advise obtaining it without a prescription where one is required."],"requiresHuman":["Starting or changing antifungal treatment for a patient."]},"ethics":{"considerations":["Medicines with pregnancy warnings need careful consent and counselling.","Antifungal resistance is a growing public health concern."],"affectedParties":["Patients with fungal infections","Pregnant people","Prescribers and pharmacists"]},"owners":{"steward":"The prescriber and the pharmacist for each patient; medicines regulators authorize products.","roles":[],"masterSystems":["National medicines registers"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.ibrexafungerp","Wikidata: Q27273787 (https://www.wikidata.org/wiki/Q27273787)"]},"properties":{"applicability":"required","items":["Stereochemical identity: Verified isomeric structure and identifier set; unresolved when unsupported","Material form: Unsalted active moiety; citrate salt; other verified form; unresolved","Ibrexafungerp content: % w/w or mg/g, stating active-moiety or salt basis and water correction","Impurity profile: % w/w, ppm, or method-qualified chromatographic area %","Physical and solid-state form: Phase, crystallinity, verified polymorph or solvate identity, temperature, and humidity","Condition-dependent solubility: mg/mL or mol/L with solvent, pH, temperature, material form, and equilibration method","Antifungal susceptibility result: MIC in µg/mL with species, isolate, method, pH, medium, and incubation conditions","Exposure evidence: AUC in ng·h/mL, Cmax in ng/mL, and half-life in h, with regimen and population","Use and handling constraints: Links to dated product labels, applicable safety data sheets, specifications, and jurisdictional records"]},"recognition":{"applicability":"required","items":["Identified by product label, active ingredient name and pack details rather than by appearance alone."]},"capabilities":{"applicability":"required","items":["Resolve an ibrexafungerp record against verified structure and material-form references.","Normalize measured quantities to an explicit active-moiety or citrate basis.","Compare a batch with the specification required for its intended laboratory or pharmaceutical role.","Select preparation and storage conditions supported for the actual material form.","Compare antifungal results while preserving isolate, assay, and evidence limitations.","Flag unsupported use claims or missing safety evidence for qualified review."]},"hazards":{"applicability":"required","items":["Risk of harm to a developing fetus.","Gastrointestinal side effects.","Interactions with other medicines."]},"interfaces":{"applicability":"required","items":["The Federal Food, Drug, and Cosmetic Act, enacted by the United States Congress and administered by the Food and Drug Administration, governs ibrexafungerp drug products marketed in the United States."]},"context":{"applicability":"required","items":["Ibrexafungerp is encountered as an active pharmaceutical ingredient in oral antifungal medicines and as a compound in antifungal research.","Analytical and pharmaceutical settings examine its identity, purity, formulation and activity against susceptible fungi."]}},"sources":[{"title":"Wikidata item Q27273787: ibrexafungerp","url":"https://www.wikidata.org/wiki/Q27273787","note":"identity and sense of the item"},{"title":"Wikipedia: Ibrexafungerp","url":"https://en.wikipedia.org/wiki/Ibrexafungerp","note":"general description of the item"}],"openQuestions":["Which authoritative chemical identifiers map specifically to unsalted ibrexafungerp and which to its citrate, and how should those forms be represented within this registry entry?","Which public specifications establish ibrexafungerp solid forms, purity limits, condition-dependent solubility, thermal behavior, and bulk-material stability?","Which applicable safety data sheets establish GHS classifications and occupational exposure limits, or explicitly document that no limit has been established?","Which validated susceptibility methods and interpretive criteria support ibrexafungerp decisions for each fungal species, and where is clinical relevance unresolved?","What are the current jurisdiction-specific product authorizations, supply conditions, and outstanding lot or manufacturing restrictions?"],"resources":{"spec":"/models/things/publications/thing-q27273787/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q27273787/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T10:24:24Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:29+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}